WO1993010795A1 - Emollient topique destine a la prevention et au traitement de lesions induites par des troubles de la circulation - Google Patents

Emollient topique destine a la prevention et au traitement de lesions induites par des troubles de la circulation Download PDF

Info

Publication number
WO1993010795A1
WO1993010795A1 PCT/US1991/008840 US9108840W WO9310795A1 WO 1993010795 A1 WO1993010795 A1 WO 1993010795A1 US 9108840 W US9108840 W US 9108840W WO 9310795 A1 WO9310795 A1 WO 9310795A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
glucose
skin
mixture
lesions
Prior art date
Application number
PCT/US1991/008840
Other languages
English (en)
Inventor
Joan B. Hinson
Original Assignee
Hinson Joan B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hinson Joan B filed Critical Hinson Joan B
Priority to CA002101169A priority Critical patent/CA2101169A1/fr
Priority to PCT/US1991/008840 priority patent/WO1993010795A1/fr
Priority claimed from CA002101169A external-priority patent/CA2101169A1/fr
Publication of WO1993010795A1 publication Critical patent/WO1993010795A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Definitions

  • This invention relates generally to the art of medicine and more particularly to the art of treatment of skin lesions, skin ulcers, and other skin maladies, and the treatment of some circulatory disorders, and as a delivery device for transporting topically applied drugs through intact skin.
  • a topical emollient comprising of a combination of glucose and insulin.
  • the topical emollient is utilized in a process wherein the mixture is applied to the affected surface for nourishment thereof and promotion of healing.
  • a source of glucose and insulin applied to a lesion, promoted the healing of the affected surface. This is surprising since it has here-to-fore been felt that insulin would not pass through the skin surface.
  • the insulin mixture provides or stimulates nourishment to the affected area.
  • the aqueous glucose and insulin mixture enhances the therapeutic benefits of other topically applied medications.
  • topical applications of hydrocortisone cream when applied according to the claimed invention, show increased therapeutic benefits consistent with an enhanced uptake or more efficient utilization of the absorbed drug.
  • the claimed invention will enable faster healing and lower concentrations of drugs to be topically applied to affected areas. This will not only lower the cost of treatment but may significantly reduce undesirable drug side effects. As the effective drug concentration is lowered, dose-responsive side effects will be lessened. In addition, drugs which may not ordinarily be administered through the skin may become candidates for topical administration via the claimed process.
  • the effective doses to date contained an excess concentration of both insulin and glucose. Since the insulin/glucose mixture is extremely safe as topically applied and relatively inexpensive, the critical lower limit of activity has not been determined. In addition, the minimum effective concentrations of the claimed invention may vary widely depending upon the age, general health, and the surface integrity of the patient's skin.
  • the insulin/glucose emollient is kept cool and away from strong light. Under these conditions, it has been found that the emollient remains stable and effective for at least several weeks.
  • the emollient is topically applied to the affected area by gloved hand on intact skin, keeping the skin moist for at least 10 minutes and using a sterile gauze pad to apply the solution to broken skin areas to keep affected area moist for at least 10 minutes.
  • other topical medications may be applied to the affected surface.
  • the preferred insulin source is a mixture of 70 % NPH insulin and 30 % regular insulin. This ratio provides both long duration insulin (NPH) and a quicker response insulin (regular) though successful results have been obtained when both forms of insulin were used individual /.
  • EXAMPLE 1 A male diabetic patient 53 years of age had open diabetic lesions on one foot and ankle consisting of multiple lesions having an area of one to one and one-half (1-1 1/2) square inches in various stages of skin break down. The trial was conducted by applying three times a day a topical ointment of 0.6 units/ml of regular insulin in a 5% glucose solution. Within five days improvement of the patients condition had occurred. The patient was discharged from the hospital and instructed to continue the application of the mixture.
  • EXAMPLE 2 An elderly diabetic male patient was homebound because of diabetic neuropathy. The patient had a scalp ulcer approximately one and one-half (1 1/2) inches in diameter. The patient had been treated about two (2) years with very little success. The scalp ulcer was treated with a mixture of 2.0 units/ml of NPH insulin in a strained honey solution. This mixture was applied once a day and within two (2) weeks the ulcer was healed.
  • EXAMPLE 3 A 61 year old female patient suffering with severe varicose veins and phlebitis was treated with a 0.4 units/ml of insulin (a combination of 70% NPH insulin and 30 % regular insulin) in a 2% glucose solution. Prior to treatment the patient suffered almost constant pain even early in the morning. This had been a constant problem for thirty (30) years. The mixture was kept cool and away from light and was applied to the legs and feet three (3) times a day at meal time. After five (5) days of treatment the patient was free of pain in the feet and legs even at the end of the day. This was the first comfort that the patient had in some thirty (30) years. After fifteen (15) months there have been no symptoms of phlebitis and there has been a slow but constant reduction in the size of the varicosities.
  • insulin a combination of 70% NPH insulin and 30 % regular insulin
  • a 38 year old female patient was suffering from a skin rash on her wrist.
  • One half of the affected rash area was treated with a topical ointment of 0.5% hydrocortisone cream.
  • the other half of the rash was treated with a mixture of 0.4 units/ml insulin (a combination of 70% NPH insulin and 30% regular insulin) and 2% glucose followed by an application of 0.5% hydrocortisone cream.
  • a marked increase in the healing and recovery of the affected area was noted in the portion of the rash treated with the hydrocortisone/insulin/glucose mixture.
  • the emollient and process of this invention provide a topical emollient which prevents and promotes healing of lesions and ulcers caused by circulatory problems and increases the effectiveness of other topical medicines applied in conjunction with the claimed invention.
  • Many variations are apparent to those of skill in the art from a reading of the above description which is exemplary in nature. Such variations are embodied within the spirit and scope of this invention as measured by the following appended claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un émollient topique destiné au traitement de lésions induites par des troubles de la circulation comprend une source de glucose et d'insuline. L'émollient topique est utilisé dans le cadre d'un procédé selon lequel l'émollient est appliqué à la surface affectée afin de la nourrir et d'en favoriser la cicatrisation. L'émollient améliore également les bienfaits thérapeutiques d'autres médicaments qui peuvent être appliqués de manière topique conjointement avec le mélange d'insuline et de glucose.
PCT/US1991/008840 1991-11-27 1991-11-27 Emollient topique destine a la prevention et au traitement de lesions induites par des troubles de la circulation WO1993010795A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002101169A CA2101169A1 (fr) 1991-11-27 1991-11-27 Emollient topique pour prevenir et traiter les lesions d'origine circulatoire
PCT/US1991/008840 WO1993010795A1 (fr) 1991-11-27 1991-11-27 Emollient topique destine a la prevention et au traitement de lesions induites par des troubles de la circulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002101169A CA2101169A1 (fr) 1991-11-27 1991-11-27 Emollient topique pour prevenir et traiter les lesions d'origine circulatoire
PCT/US1991/008840 WO1993010795A1 (fr) 1991-11-27 1991-11-27 Emollient topique destine a la prevention et au traitement de lesions induites par des troubles de la circulation

Publications (1)

Publication Number Publication Date
WO1993010795A1 true WO1993010795A1 (fr) 1993-06-10

Family

ID=25676411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/008840 WO1993010795A1 (fr) 1991-11-27 1991-11-27 Emollient topique destine a la prevention et au traitement de lesions induites par des troubles de la circulation

Country Status (1)

Country Link
WO (1) WO1993010795A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2369572A (en) * 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
WO2002051352A2 (fr) * 2000-12-26 2002-07-04 Yao Zhu Nouvelles utilisations de l'insuline et de la pancreatine
WO2010109239A1 (fr) 2009-03-27 2010-09-30 First Water Limited Compositions multicouches et pansements
WO2015059501A1 (fr) 2013-10-24 2015-04-30 First Water Limited Pansements hydrogel souples pour plaies
US9056127B2 (en) 2008-01-17 2015-06-16 First Water Limited Hydrogel composition based on co-polymer carrying multiple pendant sulphonic groups for use as a wound dressing
WO2020150548A1 (fr) 2019-01-17 2020-07-23 Scapa Tapes Na Composition destinée à être utilisée dans des pansements

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847083A (en) * 1986-04-02 1989-07-11 Dermasciences, Inc. Two-step procedure for indolent wound healing and aqueous medium and topical ointment used in connection therewith
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
US4886786A (en) * 1985-08-01 1989-12-12 Lindstrom Richard L Additive for irrigation solution or surgical solution
US4889844A (en) * 1985-10-22 1989-12-26 Silvetti Sr Anthony N Fructose containing wound healing preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886786A (en) * 1985-08-01 1989-12-12 Lindstrom Richard L Additive for irrigation solution or surgical solution
US4889844A (en) * 1985-10-22 1989-12-26 Silvetti Sr Anthony N Fructose containing wound healing preparation
US4847083A (en) * 1986-04-02 1989-07-11 Dermasciences, Inc. Two-step procedure for indolent wound healing and aqueous medium and topical ointment used in connection therewith
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2369572A (en) * 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
US8557770B2 (en) 2000-11-29 2013-10-15 Pharmecosse Ltd. Method of preventing or reducing scarring of human skin
US9308240B2 (en) 2000-11-29 2016-04-12 Pharmecosse Limited Method of preventing or reducing scarring of human skin
WO2002051352A2 (fr) * 2000-12-26 2002-07-04 Yao Zhu Nouvelles utilisations de l'insuline et de la pancreatine
WO2002051352A3 (fr) * 2000-12-26 2002-11-07 Yao Zhu Nouvelles utilisations de l'insuline et de la pancreatine
US9056127B2 (en) 2008-01-17 2015-06-16 First Water Limited Hydrogel composition based on co-polymer carrying multiple pendant sulphonic groups for use as a wound dressing
WO2010109239A1 (fr) 2009-03-27 2010-09-30 First Water Limited Compositions multicouches et pansements
US8871992B2 (en) 2009-03-27 2014-10-28 First Water Limited Multilayer compositions and dressings
WO2015059501A1 (fr) 2013-10-24 2015-04-30 First Water Limited Pansements hydrogel souples pour plaies
US10688215B2 (en) 2013-10-24 2020-06-23 First Water Limited Flexible hydrogel wound dressings
WO2020150548A1 (fr) 2019-01-17 2020-07-23 Scapa Tapes Na Composition destinée à être utilisée dans des pansements

Similar Documents

Publication Publication Date Title
US5145679A (en) Topical emollient for prevention and treatment of circulatory induced lesions
US4678668A (en) Method of reducing soft tissue swelling and pain
CH653892A5 (de) Wundheilmittel zur bedeckung von wunden und verbrennungen.
JPH01503146A (ja) 身体組織の治療方法および身体組織への医薬の投与方法
Milburn et al. Treatment of scleroderma skin ulcers with a hydrocolloid membrane
WO1993010795A1 (fr) Emollient topique destine a la prevention et au traitement de lesions induites par des troubles de la circulation
US20020182263A1 (en) Pharmaceutical composition comprising dimethylsulfoxide and ozone
US5331012A (en) Topical pharmaceutical preparation for fever blisters and other viral infections and method of use
US5945119A (en) Therapeutic preparations containing caesium ions
US6011061A (en) Therapeutic methods and preparations using rubidium ions
US5576329A (en) Method for treating tendon or joint inflammation with papaverine HCL
Knight Medical management of pressure sores
RU2177314C2 (ru) Состав с антисептическими, репаративными и болеутоляющими свойствами
CA2101169A1 (fr) Emollient topique pour prevenir et traiter les lesions d'origine circulatoire
US20030092682A1 (en) Use of doxycycline for treatment of certain skin and mouth ailments
CN108635362B (zh) 一种治疗糖尿病足的药物组合物
CN1634429A (zh) 一种治疗疖、疽、痈、疔毒及烧烫伤的药物组合物
RU2357747C1 (ru) Способ лечения больных псориатической болезнью
RU2063752C1 (ru) Лекарственное средство для лечения старческих, диабетических и лучевых длительно незаживающих ран
US6395779B1 (en) Method of treatment using peroxidized lipids
RU2084230C1 (ru) Способ лечения псориаза
PharmD et al. Topical metronidazole for arterial insufficiency ulcers
CN113952364A (zh) 一种外用消炎制剂
JP2004262772A (ja) グリチルリチン含有経皮製剤
RU2163485C1 (ru) Способ о.ф. и с.а. лапиных лечения ожогов и других поражений кожи с использованием препарата "дарина"

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2101169

Country of ref document: CA

122 Ep: pct application non-entry in european phase